Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
0.2550
-0.0012 (-0.47%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 27, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
September 26, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Cantor Global Healthcare Conference
September 25, 2023
Via
Investor Brand Network
Cybin to Participate in the Cantor Global Healthcare Conference
September 25, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting
September 22, 2023
Via
Investor Brand Network
Cybin Announces Date of Annual and Special Meeting of Shareholders
September 21, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study
September 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
September 21, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notification of Approval for U.S. Patent Covering Deuterated Tryptamines
September 05, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
September 20, 2023
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
September 05, 2023
From
Cybin Inc.
Via
Business Wire
Cybin to Acquire Small Pharma Inc.
August 28, 2023
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for...
Via
Newsfile
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’
August 28, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin to Acquire Small Pharma Inc.
August 28, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Renewed ATM Program of up to US$35M
August 24, 2023
Via
Investor Brand Network
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
August 23, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Featured in Proactive Interview
August 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Preparing for CYB003 Capsule Manufacturing for Potential Phase 3 Trial
August 17, 2023
Via
Investor Brand Network
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
August 17, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures New US Patent Supporting Its CYB003 Program
August 15, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
August 15, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2024 Financial Results, Business Highlights
August 14, 2023
Via
Investor Brand Network
Cybin Reports First Quarter Financial Results and Recent Business Highlights
August 14, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Closing of Marketed Public Offering
August 04, 2023
Via
Investor Brand Network
Cybin Announces Closing of Overnight Marketed Public Offering of Units
August 04, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort
August 02, 2023
Via
Investor Brand Network
Exposures
Product Safety
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
August 02, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Overnight Public Offering
August 01, 2023
Via
Investor Brand Network
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
August 01, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Announces Overnight Marketed Public Offering of Units
July 31, 2023
From
Cybin Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.